Alcon Science | United States

This page is available in English. Select below for other countries.

Select other country
  • Dry Eye
Rethinking the Dry Eye Disease Treatment Paradigm
Nov 04, 2026
  • Dry Eye
Rethinking the Dry Eye Disease Treatment Paradigm
Nov 04, 2026

John Hovanesian, MD, moderates a discussion with Mark Milner, MD, and Carlton Yuen, MD, exploring the role of the neurosensory system in dry eye disease (DED) and TRPM8-targeted therapy with acoltremon ophthalmic solution 0.003%.


The faculty examines how corneal sensory nerves contribute to tear production and how neurosensory dysfunction may drive the signs and symptoms of DED. The discussion explores the mechanism and clinical evidence for acoltremon 0.003%, a first-in-class TRPM8 agonist, including its effects on tear production, dry eye symptoms, corneal and conjunctival staining, and treatment tolerability.


Through clinical perspectives and real-world cases, the panel also considers how this novel neuromodulator may fit into contemporary DED management, including in early DED, concomitant with other DED therapies, and for ocular surface optimization with cataract surgery.

↑